Bradley A. Arrick MD, PhD |
| Contact Information: |
|
Phone: (603) 653-6181
|
|
Fax: (603) 653-6191
|
| Email: not given |
|
| Institution Affiliations: |
| Associate Professor of Medicine (Hematology/Oncology) |
| Acting Chief, Section of Hematology and Oncology |
| Department of: MEDICINE |
| Section: Hematology/Oncology |
| Specialty: Hematology/Oncology |
| Joined Staff: 1990 |
| Cancer Center Membership: |
| Clinical Interests: |
| Cancer Genetics |
| Familial Cancer Program |
| Breast Cancer |
| Genetic Testing |
|
| Board Certified: |
| Hematology/Oncology |
| Medical Oncology 1989 |
| Internal Medicine 1987 |
|
| Cornell University Medical College, New York, NY 1984 |
| PhD, Rockefeller University, New York, NY, (Biochemistry) 1983 |
| University of California (San Diego) Medical Center, San Diego, CA, (Internal Medicine) 1984-87 |
| University of California (San Francisco) Hospitals/Clinic, San Francisco, CA, (Medical Oncology) 1987-89 |
| Dr. Arrick received his BA in chemistry and biology from Wesleyan University in 1977, his Ph.D. in cellular biochemistry from the Rockefeller University in 1983, and his M.D. from Cornell University Medical College in 1984. Following a residency in internal medicine at the University of California at San Diego, he completed an oncology fellowship at the University of California at San Francisco and post-doctoral research training at Genentech, Inc. He joined the Dartmouth Medical School faculty in 1990 as an Assistant Professor of Medicine, and he became Associate Professor of Medicine in 1996. He is Medical Director of the Familial Cancer Program at the Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center. He is an oncologist for the Breast Cancer Program. |
| Dr. Arrick's research interests include the study of transforming growth factor-beta, one of the most versatile and potent of growth regulatory proteins. In particular, the mechanisms by which tumor cells regulate their production of TGF-beta, and the biological consequences of diminished responsiveness to TGF-beta, are under study, with a focus on breast cancer. In the field of cancer genetics, Dr. Arrick's lab is studying the expression and function of mRNA splice variants of BRCA1, a breast/ovarian cancer susceptibility gene. Through the familial Cancer Program of the Norris Cotton Cancer Center, his team is pursuing the development of more effective educational approaches for genetic counseling. The translational control of growth factor synthesis is another area of research interest. In these studies, Dr. Arrick is exploring the molecular mechanisms which affect the translational efficiency of messenger RNAs which encode growth-regulatory proteins. |
| Meiling Lu and Bradley A. Arrick. 2000. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: Evidence for both common and distinct activities of wildtype and mutant forms. Oncogene 19: 6351-6360. |
| Stephen W. Tobin, Mary Kay Brown, Karen Douville, Drew C. Payne, Alan Eastman, and Bradley A. Arrick. 2001. Inhibition of transforming growth factor-b signaling in MCF-7 cells results in resistance to tumor necrosis factor-a: A role for Bcl-2. Cell Growth & Differentiation 12: 109-117. |
| Stephen W. Tobin, Karen Douville, Ulrike Benbow, Constance E. Brinckerhoff, Vincent A. Memoli, and Bradley A. Arrick. 2002. Consequences of altered TGF-b expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene 21: 108-118. |
| William B. Archey, Kristen A. McEachern, Mark Robson, Kenneth Offit, Susan A. J. Vaziri, Graham Casey, Åke Borg, and Bradley A. Arrick. 2002. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene, 21: 7034-7041. |
| Kristen A. McEachern, William B. Archey, Karen Douville, and Bradley A. Arrick. 2003. BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. Journal of Cellular Biochemistry, 89:120-132. |
| Kuhn JC, Siegel A, Poplack S, Arrick B. Chest wall recurrence of breast cancer detected by scintimammography. Clinical Nuclear Medicine 25:104-106, 2000. |
| Archey W, Sweet MP, Alig G, and Arrick BA. Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3. Cancer Research, 59:2292-2296, 1999. |
| Lu M, Conzen SD, Cole CN, and Arrick BA. Characterization of functional splice variants of BRC1 expressed in non-malignant and tumor-derived breast cells. Cancer Research 56:4578-4581, 1996. |
|
|
|
|
Mailing Address:
Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756
|
|
